User:Mr. Ibrahem/Fexinidazole
 | |
| Clinical data | |
|---|---|
| Other names |
|
| AHFS/Drugs.com | Monograph |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C12H13N3O3S |
| Molar mass | 279.31 g·mol−1 |
| 3D model (JSmol) | |
| |
Fexinidazole is a medication used to treat African trypanosomiasis (sleeping sickness) cause by Trypanosoma brucei gambiense.[1] It is effective against both first and second stage disease.[1] Some evidence also supports its use in Chagas disease.[4] It is taken by mouth.[4]
Common side effects include nausea, vomiting, headache, and trouble sleeping.[2] Other side effects may include QT prolongation, psychosis, and low white blood cells.[5] It is unclear if use during pregnancy or breast feeding is safe.[5] Fexinidazole is in the antiparasitic and the nitroimidazole family of medications.[4] It is believed to work by turning on certain enzymes within the parasites that result in their death.[2]
Fexinidazole was first described in 1978.[6] It was given a positive opinion by the European Medicines Agency in 2018 and approved for medical use in the United States in 2021.[2][7] It is on the World Health Organization's List of Essential Medicines.[8] Development for sleeping sickness was funded by the Drugs for Neglected Diseases initiative in collaboration with Sanofi.[9]
References[edit]
- ^ a b c DIMITROVA, Elena Kostadinova (22 January 2019). "Fexinidazole Winthrop H-W-2320". European Medicines Agency. Archived from the original on 18 January 2021. Retrieved 12 November 2019.
- ^ a b c d "Fexinidazole Winthrop (fexinidazole)" (PDF). EMA. Archived from the original (PDF) on 2 January 2021. Retrieved 12 November 2019.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 28 August 2021. Retrieved 10 September 2020.
- ^ a b c Deeks, ED (February 2019). "Fexinidazole: First Global Approval". Drugs. 79 (2): 215–220. doi:10.1007/s40265-019-1051-6. PMID 30635838.
- ^ a b "Fexinidazole Winthrop" (PDF). EMA. Archived from the original (PDF) on 12 November 2019. Retrieved 12 November 2019.
- ^ Gil, Carmen; Rivas, Luis (2017). Drug Discovery for Leishmaniasis. Royal Society of Chemistry. p. 30. ISBN 9781788012584. Archived from the original on 28 August 2021. Retrieved 12 November 2019.
- ^ Research, Center for Drug Evaluation and (21 June 2022). "Novel Drug Approvals for 2021". FDA. Archived from the original on 3 March 2022. Retrieved 28 October 2022.
- ^ "World Health Organization model list of essential medicines: 21st list 2019" (Document). 2019. hdl:10665/325771.
{{cite document}}: Cite document requires|publisher=(help) - ^ "Fexinidazole – DNDi". www.dndi.org. Archived from the original on 29 April 2020. Retrieved 12 November 2019.